-
2023-504989-37-00
5
Metastatic Squamous Non-small Cell Lung Cancer
-
2025-523461-17-01
5
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2025-524316-11-00
5
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-521562-95-00
5
2025-12-30
Previously Untreated Advanced (Unresectable or Metastatic) Melanoma
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer
-
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
-
2024-514048-98-00
5
2025-01-30
Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cance
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2023-508875-35-00
5
2025-09-01
Heart condition
-
2024-517423-40-00
5
2025-06-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-517335-46-00
4
2025-06-05
Bladder cancer
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2023-504263-16-00
5
2023-05-25
This is an extension study designed to provide continued treatment for
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-513968-25-00
5
2025-04-28
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-511650-50-00
5
2025-01-17
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-505989-29-00
5
2024-11-21
Extensive stage small cell lung cancer (ES-SCLC)